| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 1.23 | 9.8% | 485.7% |
| Total Income | 1.23 | 9.8% | 485.7% |
| Expenditure | 55.20 | 1.3% | 1.4% |
| PBT | — | ||
| Net Profit | -50.58 | 3.8% | 3.7% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.32 | 21.9% | 27.3% |
Prime Medicine Reports Q3 2025 Results
04 May 2026 · 4 May, 7:36 am
Summary
Prime Medicine, Inc. issued a press release on November 7, 2025, announcing its financial results and business highlights for the quarter ended September 30, 2025. The press release was furnished as an exhibit to a Current Report on Form 8-K. The information contained within the press release is furnished and not deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934.
Key Highlights
- 1
Prime Medicine, Inc. announced its financial results and business highlights for the quarter ended September 30, 2025.
- 2
A press release was issued on November 7, 2025, regarding the financial results.
- 3
The press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K.
- 4
The company reported results for the quarter ended September 30, 2025.
Informational and educational content only. Not investment advice.